

FORM PTO-1082  
Docket:



AMENDMENT TRANSMITTAL LETTER

TECH CENTER 1600/2900

APR 25 2002

RECEIVED

In re application of:

Woodward et al

Serial No.:

09/848,249

Examiner:

Fay, Z

Filed:

5/3/01

Group Art Unit:

1674

For:

Alpha-2-Adrenergic

COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

☐ No additional fee is required.

The filing fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA
TOTAL		MINUS	20	
INDEP.		MINUS	3	
<input type="checkbox"/> First Presentation of Multiple Dep. Claim				

SMALL ENTITY

RATE	ADDIT. FEE
x 9	
x 42	
+140	
Total Addit. Fee	

OTHER THAN  
SMALL ENTITY

RATE	ADDIT. FEE
x 18	
x 84	
+280	
Total Addit. Fee	

☐ Please charge my Deposit Account No. \_\_\_\_\_ the amount of \$ \_\_\_\_\_.

☒ A check in the amount of \$ 110 is attached for an Extension of Time.

☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 01-0885.

☒ Any additional filing fees required under 37 CFR 1.16.

☒ Any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

Frank J. Uxa

Attorney for Applicant

Registration Number: 25,612

4 Venture, Suite 300  
Irvine, CA 92618  
phone (949) 450-1750  
fax (949) 450-1764



D-2910

UNITED STATES PATENT AND TRADEMARK OFFICE  
PATENT

#5A  
m.m.  
5/1/02

In re application of:  
WOODWARD et al

Serial Number: 09/848,249

Filed: May 03, 2001

For: ALPHA-2-ADRENERGIC  
AGONIST/FATTY ACID  
COMPOSITIONS

) Examiner: Fay, Zohreh  
)  
) Group Art Unit: 1614  
)  
)  
)  
)  
)  
)

RECEIVED  
APR 25 2002  
TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on or before

APR 17, 2002  
Frank J. [Signature]  
Attorney  
Title  
Date 4/17/02

RESPONSE A

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Please revise the above-identified application as follows:

IN THE CLAIMS

Rewrite claims 1 and 23 to read as follows:

Sub  
A1 C1  
1. (Amended) A composition comprising:  
an alpha-2-adrenergic agonist, and  
a fatty acid component, the fatty acid component being  
present in a complex with the alpha-2-adrenergic agonist; the  
complex remaining substantially intact in an aqueous environment.

A2  
Sub  
C3  
23. (Amended) A composition comprising:  
5-bromo-6-(2-imidazolylamino) quinoxaline; and  
a linolenic acid component,

39

X